Lineage Cell Therapeutics (LCTX) Misses Q4 EPS by 11c

Lineage Cell Therapeutics (NYSE: LCTX) reported Q4 EPS of ($0.15), $0.11 worse than the analyst estimate of ($0.04). Revenue for the quarter came in at $14.7 million versus the consensus estimate of $2.57 million.

For earnings history and earnings-related data on Lineage Cell Therapeutics (LCTX) click here.

You May Also Be Interested In

• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Oracle raises full year profit guidance, stock rises after hours
• Copart to buy ACV for $1.9 billion in cash deal